Dipna Pharmachem (543594)

Score breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Latest quarter sales of ₹74 Cr are substantial relative to the ₹19 Cr market cap, showing the business has real operating scale.
• P/E of 11.60 is modest, and the 314.71% profit growth reflects a sharp earnings recovery from a low base.
• Piotroski F-Score of 6/9 points to improving fundamental health across profitability, leverage and asset efficiency.
• Stock is near its 52-week low of ₹7.10, suggesting much of the pessimism may already be priced in.

Concerns

• Sales growth is deeply negative at -18.85%, indicating a contracting top line rather than a growing business.
• Net margin is razor-thin at roughly 1.35% (₹1 Cr net profit on ₹74 Cr sales), leaving almost no cushion for cost shocks.
• ROCE of only 6.64% is weak and likely below a reasonable cost of capital, suggesting poor value creation.
• No dividend and no disclosure of book value, debt/equity, or promoter holding make it hard to assess balance sheet quality and insider conviction.

AI Analysis

At ₹7.70, with a market cap of only ₹19 Cr, the market has already marked Dipna Pharmachem down harshly; the stock trades near the bottom of its ₹7.10–₹25.00 52-week range. The trailing P/E of 11.60 looks cheap, and a 314.71% profit growth figure catches the eye. But Buffett's first rule is not to lose money, and Graham's rule is to have a margin of safety. Here I see a small pharma business with a real turnover—₹74 Cr in the latest quarter—but a net profit of just ₹1 Cr. That is roughly a 1.35% net margin. Such a thin margin leaves very little room for error. Sales are shrinking, down 18.85%, which is the opposite of what I want in a growing enterprise. The 6.64% ROCE is also modest; it tells me the company is not yet earning a high return on capital employed. The Piotroski F-score of 6/9 is acceptable, but it is the only comfort. With no dividend and no disclosed book value, debt/equity or promoter holding, I cannot apply my usual value tests. The PEG ratio of 0.04 is a red flag in disguise: Mr. Market is not paying for growth because it does not trust the earnings spike. This looks more like a possible turnaround than a wonderful business. I would insist on several quarters of positive, consistent earnings and stabilised sales before acting. The price may look like a cigar butt, but with a 70% drop from the high, the risk of a value trap is real. I need evidence that this profit is sustainable and capital is being deployed productively before I call it an investment.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer